PLAU anticorps (AA 396-426)

N° du produit ABIN3032244

Détail du produit anti-PLAU anticorps

Antigène: PLAU (Plasminogen Activator, Urokinase (PLAU))

Épitope: AA 396-426

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PLAU est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunofluorescence (IF)

Purification: Purified

Immunogène: A portion of amino acids 396-426 from the human protein was used as the immunogen for this UPA antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: Titration of the UPA antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,IHC (Paraffin): 1:10-1:50,Immunofluorescence: 1:10-1:50,Flow Cytometry: 1:10-1:50

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the UPA antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Détails sur PLAU

Antigène: PLAU (Plasminogen Activator, Urokinase (PLAU))

Autre désignation: UPA (PLAU Produits)

Synonymes: anticorps PLAU, anticorps u-PA, anticorps ATF, anticorps BDPLT5, anticorps QPD, anticorps UPA, anticorps URK, anticorps uPA, anticorps UPAM, anticorps plasminogen activator, urokinase, anticorps urokinase-type plasminogen activator, anticorps PLAU, anticorps CpipJ_CPIJ002131, anticorps CpipJ_CPIJ006543, anticorps CpipJ_CPIJ013396, anticorps CpipJ_CPIJ013623, anticorps Plau

Sujet: PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.

UniProt: P00749

Pathways: Cellular Response to Molecule of Bacterial Origin, Carbohydrate Homeostasis, Autophagy, Smooth Muscle Cell Migration